The most important problem in fat transplantation is the unpredictable rates of resorption. Deferoxamine (DFO) is an iron-chelating agent with many useful functions including stimulating angiogenesis and antioxidant nature. The purpose of the study is to evaluate the effects of DFO on fat graft viability in rat model. A total of 24 Wistar rats were divided into three groups and 0.5 g of the left inguinal fat pad was extracted. In control group, fat grafts were implanted to the parascapular area without performing any procedure. In sham group, they were implanted in 0.2 mL saline solution followed by serial saline injections for 1 month. In the study group, fat grafts were implanted in 0.2 mL saline solution and 300 mg DFO followed by serial DFO injections for 1 month. At the postoperative second month, fat grafts were taken back and sent for histopathologic examination. The weight measurements of biopsy specimens in the study group demonstrated significantly higher than in the other two groups. Inflammation and fibrosis rates were also found to be significantly higher in the study group compared with the other groups; however, no significant difference in the apoptosis rates was detected between the groups. Fat grafts enriched with DFO showed significant increase in fatty tissue content in the study group compared with the control and sham groups. DFO increases the fat graft survival in rats and it may be a useful addition in autologous fat grafting procedures to increase fat graft viability and obtain maximal long-term durability.

BackgroundIn the present study we evaluated clinical and echocardiography findings of pregnant women with dyspnea.Material/MethodsPregnant women with and without dyspnea and admitted to the Gynecology and Obstetrics Clinic of a tertiary hospital between December 2017 and June 2018 were enrolled in this case-control study. All patients underwent echocardiography in the third trimester (≥27 weeks). Pregnant women who were older than 18 years, who had dyspnea, and who were in the third trimester of their pregnancy (≥27 weeks) were included in the study.ResultsLeft ventricle end-diastolic diameter (LVEDd) was 47.38±3.68 mm in the study group and 43,70±8,84 mm in the control group (P=0.041). On the other hand, left ventricle end-systolic diameter (LVESd) was determined to be 30.86±3.90 mm in the study group and 34,45±6,56 mm in the control group (P=0.013). Systolic pulmonary artery pressure (sPAP), calculated through tricuspid insufficiency and analyzed, was found to be 24.69±9.10 mmHg in the study group and 20.39±6.80 mmHg in the control group (p=0.038).ConclusionsWhen echocardiography findings of pregnant women with dyspnea were analyzed, it was determined that their left ventricle end-diastolic diameter (LVEDd), left ventricle end-systolic diameter (LVESd), and systolic pulmonary artery pressure (sPAP), calculated through tricuspid insufficiency, were higher than those of women in the control group, although they were within normal limit range. Therefore, we recommend that women with dyspnea should see a cardiologist and undergo an echocardiogram test so that the cardiac causes of dyspnea can be clinically revealed.

No abstract

No abstract

No abstract